JP2018513832A5 - - Google Patents

Download PDF

Info

Publication number
JP2018513832A5
JP2018513832A5 JP2017541855A JP2017541855A JP2018513832A5 JP 2018513832 A5 JP2018513832 A5 JP 2018513832A5 JP 2017541855 A JP2017541855 A JP 2017541855A JP 2017541855 A JP2017541855 A JP 2017541855A JP 2018513832 A5 JP2018513832 A5 JP 2018513832A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound according
hydrogen
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017541855A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513832A (ja
JP6769000B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/077519 external-priority patent/WO2016155593A1/zh
Publication of JP2018513832A publication Critical patent/JP2018513832A/ja
Publication of JP2018513832A5 publication Critical patent/JP2018513832A5/ja
Application granted granted Critical
Publication of JP6769000B2 publication Critical patent/JP6769000B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017541855A 2015-04-03 2016-03-28 4’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途 Expired - Fee Related JP6769000B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510157772 2015-04-03
CN201510157772.0 2015-04-03
PCT/CN2016/077519 WO2016155593A1 (zh) 2015-04-03 2016-03-28 4'-硫代核苷的新型化合物及其制备方法、药物组合物和应用

Publications (3)

Publication Number Publication Date
JP2018513832A JP2018513832A (ja) 2018-05-31
JP2018513832A5 true JP2018513832A5 (enExample) 2019-03-28
JP6769000B2 JP6769000B2 (ja) 2020-10-14

Family

ID=57004251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541855A Expired - Fee Related JP6769000B2 (ja) 2015-04-03 2016-03-28 4’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途

Country Status (8)

Country Link
US (2) US10662214B2 (enExample)
EP (1) EP3279207B1 (enExample)
JP (1) JP6769000B2 (enExample)
CN (2) CN106661077B (enExample)
AU (1) AU2016240117C1 (enExample)
CA (1) CA2975990A1 (enExample)
EA (1) EA034375B1 (enExample)
WO (1) WO2016155593A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201406080VA (en) 2012-03-28 2014-11-27 Fujifilm Corp SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE
CA2880794C (en) 2012-08-13 2018-08-28 Fujifilm Corporation Synthetic intermediate of 1-(2-deoxy-2-fluoro-4-thio-.beta.-d-arabinofuranosyl)cytosine, synthetic intermediate of thionucleoside, and methods for producing the same
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US10662214B2 (en) * 2015-04-03 2020-05-26 Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
RU2752172C2 (ru) 2016-08-31 2021-07-23 Фуджифилм Корпорэйшн Противоопухолевый агент, усилитель противоопухолевого действия и противоопухолевый набор
US10787477B2 (en) 2016-12-22 2020-09-29 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Solid form of 4′-thio-2′-fluoronucleoside phosphamide compound and preparation method therefor and use thereof
WO2019001292A1 (zh) * 2017-06-29 2019-01-03 四川科伦博泰生物医药股份有限公司 4'-硫代核苷的新型化合物的制备方法和此制备方法中的中间体
WO2019042226A1 (zh) 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 用于肿瘤治疗或预防的药物组合物、方法及其用途
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
EP4209498A1 (en) * 2018-04-19 2023-07-12 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
WO2020108343A1 (zh) * 2018-11-28 2020-06-04 四川科伦博泰生物医药股份有限公司 以4'-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
US20220281910A1 (en) * 2019-07-30 2022-09-08 Pinotbio, Inc. Dinucleotide compounds for treating cancers and medical uses thereof
CN115768432A (zh) 2020-04-23 2023-03-07 南方研究院 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128458A (en) 1990-04-20 1992-07-07 Southern Research Institute 2',3'-dideoxy-4'-thioribonucleosides as antiviral agents
US6147058A (en) 1996-04-09 2000-11-14 Yamasa Corporation 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine
JPH1087687A (ja) 1996-04-09 1998-04-07 Yamasa Shoyu Co Ltd 5−置換−1−(2−デオキシ−2−フルオロ−4−チオ−β−D−アラビノフラノシル)ウラシル
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ, インコーポレーテッド 4’−チオヌクレオシドおよびオリゴマー化合物
US7888330B2 (en) * 2005-11-09 2011-02-15 Wayne State University Phosphoramidate derivatives of FAU
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2734535A4 (en) * 2011-07-19 2014-10-22 Nanjing Molecular Res Inc 2 ', 3'-DIDEOXY-2'-ALPHA-FLUOR-2'-BETA-C-METHYL NUCLEOSIDE AND PRODRUGS THEREOF
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014197578A1 (en) * 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US10662214B2 (en) * 2015-04-03 2020-05-26 Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof

Similar Documents

Publication Publication Date Title
JP2018513832A5 (enExample)
ES2925564T3 (es) Derivados de azetidina tal como moduladores de receptores de quimiocinas y usos de los mismos
JP5271913B2 (ja) 化合物
KR101612642B1 (ko) 테노포비어 알라펜아미드 헤미푸마레이트
ES2654161T3 (es) Compuestos químicos
JP2020515610A5 (enExample)
RU2007124329A (ru) ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ
CA2938280A1 (en) 4-amino-imidazoquinoline compounds
JP2013010792A5 (enExample)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
KR101986272B1 (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
JP2013056886A5 (enExample)
KR20150046315A (ko) 테노포비르 전구약물 및 그의 약학적 용도
ES2714100T3 (es) Compuestos de quinolina fusionados como inhibidores de mTor, pi3k
JP2015508092A5 (enExample)
JP2017534657A (ja) 新型シチジン誘導体およびその適用
JP2020516616A5 (enExample)
JP2015502371A5 (enExample)
WO2015197006A1 (zh) 一种取代的氨基酸硫酯类化合物、其组合物及应用
JP6872179B2 (ja) テノホビルプロドラッグの新規な多結晶形並びにその製造方法及び用途
TWI638825B (zh) 抑制癌症及病毒之化合物
CA2552855A1 (en) Azabicyclooctan-3-one derivatives and use thereof
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP2013525290A5 (enExample)
JP2006500372A5 (enExample)